These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12018626)

  • 21. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
    Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
    J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
    Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
    Bernardi M; Biselli M; Gramenzi A
    Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus antiviral drug resistance: from the laboratory to the patient.
    Mutimer D
    Antivir Ther; 1998; 3(4):243-6. PubMed ID: 10682147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.
    Zoulim F
    Drug Saf; 2002; 25(7):497-510. PubMed ID: 12093308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lamivudine for hepatitis B after liver transplantation.
    Mutimer D
    Liver Transpl; 2001 Jun; 7(6):511-2. PubMed ID: 11443578
    [No Abstract]   [Full Text] [Related]  

  • 35. [The patient with uncontrolled chronic hepatitis B].
    Zarski JP; Leroy V
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S7-11. PubMed ID: 18662613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of acute rejection shortly after initiation of lamivudine therapy in a simultaneous pancreas and kidney recipient with viral hepatitis type B.
    Chudek J; Kolonko A; Ficek J; Karkoszka H; Baka-Cwierz B; Wiecek A
    Transpl Infect Dis; 2009 Dec; 11(6):553-6. PubMed ID: 19725907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture.
    Yuen LK; Locarnini SA
    J Hepatol; 2009 Mar; 50(3):445-8. PubMed ID: 19152982
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of chronic hepatitis B infection: an update.
    Mazumdar TN
    J Indian Med Assoc; 2001 Jun; 99(6):306-8, 310. PubMed ID: 11678618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of lamivudine in the treatment of chronic hepatitis B virus infection.
    Hagmeyer KO; Pan YY
    Ann Pharmacother; 1999 Oct; 33(10):1104-12. PubMed ID: 10534223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine in the treatment of HBV-related liver disease after renal transplantation: an update.
    Fabrizi F; Martin P; Bunnapradist S; Villa M; Rusconi E; Messa PG
    Int J Artif Organs; 2005 Mar; 28(3):211-21. PubMed ID: 15818543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.